CONTENTS

· Faculty
· Scientific Agenda
· Who Should Attend?
· Objectives
· CME
· Call for Abstracts
· Registration
· General Information
· Hotel   Accommodations
· Organizer

Richard T. Silver, MD, FACP
Weill Medical College of Cornell University
New York, New York

Co-Chair:
Jerry L. Spivak, MD, FACP
Johns Hopkins University
Baltimore, Maryland

Tiziano Barbui, MD
Ospedali Riuniti di Bergamo
Bergamo, Italy

Giovanni Barosi, MD
IRCCS Policlinico San Matteo
Pavia, Italy

John M. Bennett, MD
University of Rochester
Medical Center
Rochester, New York

Peter Campbell, MD
Cambridge Institute for
Medical Research
Cambridge, United Kingdom

Francisco Cervantes, MD
Hospital Clinic
University of Barcelona
Barcelona, Spain

Jorges Cortes, MD
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Nick C.P. Cross, PhD
University of Southampton
School of Medicine
Wilts, United Kingdom

H. Joachim Deeg, MD
Fred Hutchinson Cancer
Research Center
Seattle, Washington

Michael Deininger, MD, PhD
Oregon Health & Science University Cancer Institute
Portland, Oregon

D. Gary Gilliland, MD, PhD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

John Goldman, MD
Hammersmith Hospital
London, United Kingdom

Anthony R. Green, PhD, FRCP, FRCPath
Cambridge Institute for
Medical Research
Addenbrooke’s Hospital
Cambridge, United Kingdom

Rudiger Hehlmann, MD, PhD
Klinikum Mannheim
der Universität
Heidelberg Mannheim
Mannheim, Germany

Ronald Hoffman, MD
University of Illinois
at Chicago
Chicago, Illinois

Chloe James, MD
Institut Gustave Roussy
Villejuif, France

Hagop M. Kantarjian, MD
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Marie-Caroline Le Bousse-Kerdilès, PhD
University of Paris
Paul Brousse Hospital
Villejuif, France

Alan F. List, MD
H. Lee Moffitt Cancer Center
and Research Institute
Tampa, Florida

Ruben A. Mesa, MD
Mayo Clinic
Rochester, Minnesota

Alison R. Moliterno, MD
Johns Hopkins University
School of Medicine
Baltimore, Maryland

Vesna Najfeld, PhD
Mount Sinai Medical Center
New York, New York

Attilio Orazi, MD
Indiana University School of Medicine
Indianapolis, Indiana

Heike L. Pahl, PhD
University Hospital Freiburg
Freiburg, Germany

Josef T. Prchal, MD
University of Utah
Health Sciences Center
Salt Lake City, Utah

Gail J. Roboz, MD
Weill Medical College of
Cornell University
New York, New York

Giuseppe Saglio, MD
University of Turin
Hospital San Luigi Gonzaga
Orbassano-Torino, Italy

Charles L. Sawyers, MD
Memorial Sloan-Kettering
Cancer Center
New York, New York

Richard T. Silver, MD, FACP
Weill Medical College of
Cornell University
New York, New York

Radek Skoda, MD
University Hospital Basel
Basel, Switzerland

Jerry L. Spivak, MD, FACP
Johns Hopkins University
Baltimore, Maryland

Ayalew Tefferi, MD
Mayo Clinic
Rochester, Minnesota

Thursday November 8, 2007

8:15 am
Welcome and Introduction
Richard T. Silver, MD, FACP

Session I: Myelodysplasia
Chair: John M. Bennett, MD

8:30 am
Classification and morphology of myelodysplastic diseases
Attilio Orazi, MD

9:00 am
Event-associated (secondary) myelodysplasia
John M. Bennett, MD

9:30 am
Update on lenalidomide and other drugs
Alan F. List, MD

10:00 am
Arsenic in MDS
Gail J. Roboz, MD

10:30 am
Coffee break

11:00 am
What transplant and when for patients with MDS
H. Joachim Deeg, MD

11:30 am
Keynote address: Lessons from kinase inhibitors
Charles L. Sawyers, MD

12:15 pm
Panel discussion

12:30 pm
Lunch

Session II: Myelofibrosis
Chairs: Giovanni Barosi, MD and
Ayalew Tefferi, MD

1:30 pm
The role of JAK2V617F mutation in the pathogenesis and progression of myelofibrosis with myeloid metaplasia
Giovanni Barosi, MD

2:00 pm
NF-E2 in the pathophysiology of MPDs
Heike L. Pahl, PhD

2:30 pm
Is this a disease of the stem cell niche?
Ronald Hoffman, MD

3:00 pm
Coffee break

3:30 pm
Clinical and therapeutic implications of megakaryocyte-stem cell niche deregulation in primary myelofibrosis
Marie-Caroline Le Bousse-Kerdilès, PhD

4:00 pm
Transplantation in myelofibrosis
Francisco Cervantes, MD

4:30 pm
Treatment of myelofibrosis diseases: Current challenges and future prospects
Ruben A. Mesa, MD

5:00 pm
Panel discussion

5:15 pm
Adjourn

Friday, November 9, 2007

Session III: Polycythemia Vera and Essential Thrombocytopenia, Myeloproliferative Diseases
Chairs: Nick C.P. Cross, PhD and
Jerry L. Spivak, MD, FACP

8:30 am
Genetics of myeloproliferative disorders with emphasis on ET
Radek Skoda, MD

9:00 am
Erythrocytosis: Congenital and nonclonal
Josef T. Prchal, MD

9:30 am
JAK2V617F allele burden: Clinical correlates and genetic modifiers
Alison R. Moliterno, MD

10:00 am
Coffee Break

10:30 am
Risk factors for survival, leukemic transformation, and thrombosis in essential thrombocythemia and polycythemia vera: Mayo clinic experience
Ayalew Tefferi, MD

11:00 am
Mutation of JAK2V617F and clonality studies in the myeloproliferative disease
Peter Campbell, MD

11:30 am
“Modern” management of polycythemia vera
Richard T. Silver, MD, FACP

12:00 pm
Panel discussion/questions

12:15 pm
Luncheon Symposium
Emerging Uses of Immunomodulatory Drugs in the Management of Myeloproliferative Diseases and Myelodysplastic Syndromes
Supported by Celgene

Session IV: Polycythemia Vera and Essential Thrombocytopenia, Myelopro­liferative Diseases, continued
Chairs: Ronald Hoffman, MD and Richard T. Silver, MD, FACP

1:30 pm
Molecular drug targets in myeloproliferative disorders
D. Gary Gilliland, MD, PhD

2:00 pm
Pathogenesis and management of ET
Anthony R. Green, PhD, FRCP, FRCPath

2:30 pm
Leukocytosis and the risk of thrombosis in ET & PV
Tiziano Barbui, MD

3:00 pm
Coffee Break

3:15 pm
BCR-ABL negative atypical myelopro­liferative diseases
Nick C.P. Cross, PhD

3:45 pm
The fallacy of the partial cytogenetic response
Vesna Najfeld, PhD

4:15 pm
How can one mutation explain 3 different MPDs?
Chloe James, MD

4:45 pm
Selected abstracts and poster review
Chair: Jerry L. Spivak, MD, FACP
Committee: Nick C.P. Cross, PhD, Ruben A. Mesa, MD, Vesna Naijfeld, PhD

5:45 pm
Adjourn

Saturday, November 10, 2007

Session V: Chronic Myeloid Leukemia (CML)
Chairs: John Goldman, MD and Rudiger Hehlmann, MD, PhD

8:30 am
Inhibiting BCR-ABL signal trans­duction: BCR-ABL formation, mechanisms of action of the different TK inhibitors, possible downstream targets for therapy
Giuseppe Saglio, MD

9:00 am
Imatinib updated: Clinical data, dosage, toxicity, stopping, pregnancy and case history
Hagop M. Kantarjian, MD

9:30 am
Monitoring response to therapy: Cytogenetics and PCR, defining response and failure and case history
John Goldman, MD

10:00 am
Break

10:30 am
Imatinib resistance: Classifications and mechanisms of resistance
Michael Deininger, MD, PhD

11:00 am
Second and third generation tyrosine kinase inhibitors: Initial clinical results and toxicity, and case history
Jorge Cortes, MD

11:30 am
Prospective clinical trials: Questions to be addressed in 2007 (useable endpoints, statistical considerations, survey of German and international phase III studies)
Rudiger Hehlmann, MD, PhD

12:00pm
Panel discussion

12:15pm
Adjourn

This educational program is specifically designed for hematologists, internists, oncologists and other physicians, physicians-in-training, and healthcare professionals (nurses, pharmacists) interested in and/or involved in the care of patients with myeloproliferative diseases and myelodysplastic syndromes. No specialized knowledge or skill other than general familiarity with hematology or internal medicine is required for successful participation in this program.

After completion of this educational activity, participants should be able to:

• Recognize the molecular mechanisms, biology and drug targets of the myelodysplastic syndromes (MDS) and myeloproliferative diseases (MPD)
• Translate current controversies in management of MDS and MPD into improved patient outcomes
• Implement new treatment modalities in MDS and MPD
• Review the latest updates in overcoming drug resistance for MDS and MPD
• Discuss the pipeline of novel agents for MDS and MPD and their impact on future patient care

Imedex Accreditation Services, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex Accreditation Services, LLC designates this educational activity for a maximum of 17.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Participants interested in presenting data should submit abstracts online by August 16, 2007. Abstracts are subject to acceptance by the Scientific Committee. Once accepted, abstracts will be published in the final program book and scheduled for oral or poster presentation.

Acceptance notifications and guidelines for presentations will be sent on September 13, 2007. Authors of accepted abstracts who have not registered will have until October 25, 2007 to do so at the rate of $299. After this date, abstracts without registered presenters will be disregarded.

Abstract Guidelines

• Follow the online instructions
• Abstracts must be written in English
• Accepted format: Word document format, 9 point Arial font, 500 word count limit
• Use a concise title
• List affiliations of author(s) as briefly as possible, with city, state and country
• Place an asterisk (*) before the name of
  the presenting author
• Use standard and well-accepted abbreviations
• When using references, use standard and
  well-accepted formats
• Abstract content should be single-spaced, typed in lower case and contain:
  – Purpose of the study
  – Summarized description of the project
  – Results and conclusions

Submission Deadline: August 16, 2007

Click here to register for this program

Discounted . . . . . . . . . . . . . . . $299
If payment received by September 6, 2007

Regular . . . . . . . . . . . . . . . . . . $399
If payment received by November 1, 2007

Full/On-Site. . . . . . . . . . . . . . . . $499
If payment received after November 1, 2007

Group Discount(Physicians only)*. . . . . . . . . . . -$50
*cannot be combined with any other discounts

Nurses/Residents/Students* . . . . . . . . . . . . . . .$199
*Proof of eligibility must accompany registration

You may register online by November 1, 2007 or call Imedex at +1 (678) 242 0906. Registration confirmations will be issued before the meeting.

To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

Group Discounts: Each one of multiple registrants from the same institute or practice each receive a $50 discount off the published registration fees, provided all registration forms and payments are received together. Only one discount will apply per physician. Discounts are not available for the Nurse/Student/Fellow rate.

Payment: To pre-register, registration and payment must be received no later than Thursday, November 1, 2007. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure program is being held as scheduled and to confirm the meeting is not full. Registration fees must be remitted by credit card, check, or wire transfer. Checks should be payable to Imedex. To pay via wire transfer, you must add $25 to each wire transaction to cover bank charges. Include the full name of the attendee and the name of the congress: 277 – MDS. An attendee is not registered until full payment is received.

Wire to: Bank of America, ABA: 0260.0959.3, Account Info: Imedex, Inc., Account: 0000.0106.3308. If the wire originates outside the United States, please add this additional information: Clearing Bank: Bank of America, New York, Swift Code: BOFAUS3N, Clearing Account: 6550305831.

Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, congress materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the program.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at
Imedex no later than Thursday, November 1, 2007. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the congress. Substitutions are accepted with written notification. No refunds will be made if notice is received after Thursday, November 1, 2007.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this program should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event program content is subject to change without notice.

Conference Location and Registration Hours

New York Marriott at the Brooklyn Bridge
333 Adams Street
Brooklyn, New York 11201 USA
Tel.:  +1 (718) 246 7000
Fax:  +1 (718) 246 0563

The Registration and Information Desk will be staffed:
Thursday, November 8, 2007: . . . 7:30 am – 5:30 pm
Friday, November 9, 2007: . . . . . 8:00 am – 5:30 pm
Saturday, November 10, 2007: . . 8:00 am – 12:30 pm

Discounted Airfares
Contact conference travel agent, Age of Travel, for assistance with your travel needs. Age of Travel can also accommodate pre- and post-conference extensions.
Tel.: +1 (800) 523 4954 or +1 (404) 591 7120
Email: Imedex@ageoftravel.com

New York Marriott at the Brooklyn Bridge
333 Adams Street
Brooklyn, New York 11201 USA
Tel.:  +1 (718) 246 7000
Fax:  +1 (718) 246 0563
www.brooklynmarriott.com

**Room block sold out**

Located in New York City’s most celebrated neighborhood, just across the river from Manhattan
sits the New York Marriott at the Brooklyn Bridge. Fresh from an expansion and renovation, the hotel boasts a relaxed but modern atmosphere with state-of-the-art amenities. The hotel sits within Renaissance Plaza, adjacent to the Metro Tech Center and surrounding universities and is a short 5 minutes from Manhattan and the Financial District, with 9 major subway lines all within one block.

For the convenience of attendees, a limited number of rooms have been reserved until October 16, 2007 at a discounted rate of $369, single or double occupancy, plus tax, currently at 13.375% and a daily occupancy tax of $3.50. This rate is not guaranteed outside the congress dates or after October 16, 2007.

To reserve your room please contact the New York Marriott at the Brooklyn Bridge reservations department at +1 (718) 246 7000 or visit the hotel’s website at www.brooklynmarriott.com. To receive the group rate, callers must identify themselves as being with the Myeloproliferative Diseases and Myelodysplastic Syndromes group. Internet users must enter the meeting promotional code: ixdixda. Reservation requests received after October 16, 2007 may not be guaranteed the group rate.

**Room block sold out**

          4325 Alexander Drive
          Alpharetta, GA 30022-3740, USA
          Tel.: +1 (770) 751 7332
          Fax: +1 (770) 751 7334
          Email: meetings@imedex.com
          Web: www.imedex.com